SUMMARY In a single blind trial, a three day course of butoconazole nitrate cream was compared with a seven day course of miconazole nitrate cream, both applied intravaginally, in treating vaginal candidiasis. They were equally effective.
Introduction
Butoconazole is a new imidazole antifungal agent, which is highly active in vitro' and in vivo2. Its use in treating vaginal candidiasis in laboratory animals has suggested that it is more active than miconazole or clotrimazole, and that butoconazole might therefore be used in lower doses than those required for the other two drugs,3 with improvement in patient compliance.4
Patients, materials, and methods
MATERIALS
Both drugs were made up as intravaginal creams containing 2% of the active agent. The dose of butoconazole prescribed was 5 g nightly for three nights. The dose of miconazole was 10 g nightly for seven nights. The drugs were packed in identical boxes and coded, using a random number The two groups of patients were well matched (table I) for age, use of oral contraceptives, duration of symptoms before treatment, and the index of their severity. A higher proportion of patients treated with butoconazole, however, had had previous episodes of candidiasis (X' = 1 27, not significant). The mean number of days to the resolution of itching (table II) was 4-7 in the patients receiving miconazole and 4 8 in those receiving butoconazole. The mean number of days to the resolution of burning was 3 -7 in both groups. The patients' assessment of the resolution of discharge was difficult to evaluate: many patients -considered that they always had a discharge, others found discharge difficult to distinguish from leakage of cream. The microbiological cure rates for both products did not differ appreciably at either follow up visit, and over 75010 of patients were free from infection at the second visit (table III) .
No serious side effects were experienced, (table IV) but both creams led some patients to complain of stinging on application, and one patient found this severe enough to withdraw from the trial. Six patients receiving butoconazole compared with three receiving miconazole complained of odour, but this difference was not significant. The complaint of odour was not associated with anaerobic vaginosis in either group. More patients receiving miconazole complained of the preparation leaking (x = 6-44; 0 025>p>001).
Discussion
The symptomatic and mycological cure rates achieved with the two preparations did not differ appreciably and our results are comparable with those achieved using other imidazole derivatives.6 7 The treatment groups were well matched except for history of candidiasis, which was more common in those receiving butoconazole. If the activity of both drugs were equivalent, increased relapses might have been expected, giving a lower cure rate for butoconazole; but this was not seen. Nine patients (five receiving butoconazole and four miconazole) received antibiotic treatment during follow-up, and one of them (receiving miconazole) subsequently relapsed.
The incidence of side effects with both drugs was relatively high, which may have been a result of the direct and specific questions answered at the time of application. As miconazole was prescribed in a larger volume and for a longer period, it is not surprising that more patients receiving this preparation complained of leakage. Stinging or irritation has been reported with other imidazole drugs, but our complaint rate was higher than usually seen.
